Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91619098)
Hartstichting (CVON 2017-20)
Received: 3 April 2020
Accepted: 7 October 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: The study protocol was approved by the medical ethical committee of the Amsterdam Medical Centre in Amsterdam, the Netherlands. Each subject provided written informed consent.
: Not applicable.
: S.W., B.D.R., S.C.S, L.F., J.O.J., M.S., N.C.W.W. and E.K. are employed by Resverlogix Corp. & hold company’s shares and stock options. All other authors declare that they have no competing interests.